Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Epigenetic landscape influences the liver cancer genome architecture

Open access

Abstract

The accumulations of different types of genetic alterations such as nucleotide substitutions, structural rearrangements and viral genome integrations and epigenetic alterations contribute to carcinogenesis. Here, we report correlation between the occurrence of epigenetic features and genetic aberrations by whole-genome bisulfite, whole-genome shotgun, long-read, and virus capture sequencing of 373 liver cancers. Somatic substitutions and rearrangement breakpoints are enriched in tumor-specific hypo-methylated regions with inactive chromatin marks and actively transcribed highly methylated regions in the cancer genome. Individual mutation signatures depend on chromatin status, especially, signatures with a higher transcriptional strand bias occur within active chromatic areas. Hepatitis B virus (HBV) integration sites are frequently detected within inactive chromatin regions in cancer cells, as a consequence of negative selection for integrations in active chromatin regions. Ultra-high structural instability and preserved unmethylation of integrated HBV genomes are observed. We conclude that both precancerous and somatic epigenetic features contribute to the cancer genome architecture.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-018-03999-y

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Hypo- and hyper-methylation of three paired hepatocellular carcinoma genomes. a In the upper panel, the left three plots show the methylation levels of the regions of tumor genomes (y-axis) or non-cancerous genomes (x-axis) delimited according to the 15 epigenomic segments. The color indicates the number of region. The orange plots show the density of LINE-1, purple plots show the density of transcribed regions, and green plots show the density of CpG islands. These densities were calculated for each fraction of the left three images, which were divided into 100 × 100 areas. In the lower panels, the genomic regions of the upper left three plots are shown separately for active and inactive chromatin state. b Methylation levels of tumor and non-cancerous genomes in the 15 epigenomic segments. The color indicates the number of bases. c Volcano plot of the differences in the methylation levels of CpG sites between tumor and non-cancerous genomes. Each dot represents a CpG site. Red indicates that the methylation level in the tumor genome is significantly (P < 0.05 using Fisher’s exact test) higher than in the non-cancerous genome, blue indicates lower, and gray indicates P ≥ 0.05. The x-axis indicates the log2 fold-change of the methylation level; the y-axis indicates the minus log10 of the P value
Fig. 1 Hypo- and hyper-methylation of three paired hepatocellular carcinoma genomes. a In the upper panel, the left three plots show the methylation levels of the regions of tumor genomes (y-axis) or non-cancerous genomes (x-axis) delimited according to the 15 epigenomic segments. The color indicates the number of region. The orange plots show the density of LINE-1, purple plots show the density of transcribed regions, and green plots show the density of CpG islands. These densities were calculated for each fraction of the left three images, which were divided into 100 × 100 areas. In the lower panels, the genomic regions of the upper left three plots are shown separately for active and inactive chromatin state. b Methylation levels of tumor and non-cancerous genomes in the 15 epigenomic segments. The color indicates the number of bases. c Volcano plot of the differences in the methylation levels of CpG sites between tumor and non-cancerous genomes. Each dot represents a CpG site. Red indicates that the methylation level in the tumor genome is significantly (P < 0.05 using Fisher’s exact test) higher than in the non-cancerous genome, blue indicates lower, and gray indicates P ≥ 0.05. The x-axis indicates the log2 fold-change of the methylation level; the y-axis indicates the minus log10 of the P valueCC BY · PubMed Central
Fig. 2 Density of mutations in the different epigenetic states in hepatocellular carcinoma. a The distribution difference of somatic mutations that depending on the differences in size (x-axis) and tumor methylation level (y-axis) of the region delimited by 15 epigenomic segments. Red indicates the number of mutations per million bases calculated for each fraction of the images in Supplementary Fig. 5a, which were divided into 100 × 100 areas. b Comparison of the distribution of somatic mutations between the active or inactive chromatin status. The x-axis indicates the methylation level of the non-cancerous liver genome and the y-axis indicates that of the tumor. The accumulation of mutations was higher in hypo-methylated regions in the inactive chromatin. Red indicates the number of mutations per million bases calculated for each fraction of the images of the lower panel of Fig. 1a, which were divided into 100 × 100 areas. c Density of mutations in the 15 epigenomic segments. Red indicates the number of mutations per million bases calculated for each fraction of the images of Fig. 1b, which were divided into 100 × 100 areas
Fig. 2 Density of mutations in the different epigenetic states in hepatocellular carcinoma. a The distribution difference of somatic mutations that depending on the differences in size (x-axis) and tumor methylation level (y-axis) of the region delimited by 15 epigenomic segments. Red indicates the number of mutations per million bases calculated for each fraction of the images in Supplementary Fig. 5a, which were divided into 100 × 100 areas. b Comparison of the distribution of somatic mutations between the active or inactive chromatin status. The x-axis indicates the methylation level of the non-cancerous liver genome and the y-axis indicates that of the tumor. The accumulation of mutations was higher in hypo-methylated regions in the inactive chromatin. Red indicates the number of mutations per million bases calculated for each fraction of the images of the lower panel of Fig. 1a, which were divided into 100 × 100 areas. c Density of mutations in the 15 epigenomic segments. Red indicates the number of mutations per million bases calculated for each fraction of the images of Fig. 1b, which were divided into 100 × 100 areasCC BY · PubMed Central
Fig. 3 Mutation signature analysis of five hepatocellular carcinoma samples in different chromatin states or with different methylation levels. a Frequencies of the 96 substitution patterns of three extracted mutational signatures. The stability of the signature and the most similar COSMIC signature are shown in Supplementary Table 4. b Contribution of the three mutational signatures to each tumor sample according to the chromatin state. The y-axis indicates the number or contributions of each signature in the mutations. In each sample, significant differences were observed between active and inactive chromatin states (P < 2.2e–16, Pearson’s Χ2-test). The contribution of Signature B (which corresponds to COSMIC Signature 16) in active state was significantly higher than that in the inactive state (P < 2.2e–16, Pearson’s Χ2-test). c The contribution of three mutational signatures in genomic regions of different methylation levels. In each sample, the contribution was significantly different between high and low methylation levels (P < 2.2e–16, Pearson’s Χ2-test). The proportions of Signature A (which corresponds to COSMIC Signature 1) and B in highly methylated regions was significantly higher than the proportions in low methylated regions (P < 2.2e–16 in Sig. A, P < 2.8e–05 in Sig. B, Pearson’s Χ2-test). d The contributions of three signatures in 15 epigenomic segments. e Odds ratio of Signature B in a particular segment compared with the other segments. *P < 0.05, **P < 0.005, ***P < 0.0005 tested with Fisher’s t-test
Fig. 3 Mutation signature analysis of five hepatocellular carcinoma samples in different chromatin states or with different methylation levels. a Frequencies of the 96 substitution patterns of three extracted mutational signatures. The stability of the signature and the most similar COSMIC signature are shown in Supplementary Table 4. b Contribution of the three mutational signatures to each tumor sample according to the chromatin state. The y-axis indicates the number or contributions of each signature in the mutations. In each sample, significant differences were observed between active and inactive chromatin states (P < 2.2e–16, Pearson’s Χ2-test). The contribution of Signature B (which corresponds to COSMIC Signature 16) in active state was significantly higher than that in the inactive state (P < 2.2e–16, Pearson’s Χ2-test). c The contribution of three mutational signatures in genomic regions of different methylation levels. In each sample, the contribution was significantly different between high and low methylation levels (P < 2.2e–16, Pearson’s Χ2-test). The proportions of Signature A (which corresponds to COSMIC Signature 1) and B in highly methylated regions was significantly higher than the proportions in low methylated regions (P < 2.2e–16 in Sig. A, P < 2.8e–05 in Sig. B, Pearson’s Χ2-test). d The contributions of three signatures in 15 epigenomic segments. e Odds ratio of Signature B in a particular segment compared with the other segments. *P < 0.05, **P < 0.005, ***P < 0.0005 tested with Fisher’s t-testCC BY · PubMed Central
Fig. 4 Mutational signature analysis of 266 hepatocellular carcinomas. a Eight mutational signatures identified from active or inactive chromatin states of 266 HCCs. The y-axis indicates the frequency of each of the 96 substitution patterns. The stability of the signature and the most similar COSMIC signature are shown in Supplementary Table 4. b Contribution of the eight mutational signatures to each tumor in active and inactive chromatin states. The y-axis indicates the number or the contribution of mutations in each signature. HBV: hepatitis B virus-related HCCs, HCV: hepatitis C virus-related HCCs, NBNC: HCCs without HBV or HCV infection. The differences in the odds ratios among viral features are shown in Supplementary Table 5. c Odds ratio of the contribution of the signature in active and inactive chromatin
Fig. 4 Mutational signature analysis of 266 hepatocellular carcinomas. a Eight mutational signatures identified from active or inactive chromatin states of 266 HCCs. The y-axis indicates the frequency of each of the 96 substitution patterns. The stability of the signature and the most similar COSMIC signature are shown in Supplementary Table 4. b Contribution of the eight mutational signatures to each tumor in active and inactive chromatin states. The y-axis indicates the number or the contribution of mutations in each signature. HBV: hepatitis B virus-related HCCs, HCV: hepatitis C virus-related HCCs, NBNC: HCCs without HBV or HCV infection. The differences in the odds ratios among viral features are shown in Supplementary Table 5. c Odds ratio of the contribution of the signature in active and inactive chromatinCC BY · PubMed Central
Fig. 5 Integration and methylation of HBV genomes in hepatocellular carcinoma genomes. a Comparison of the methylation levels of the regions of tumor genomes (y-axis) that included the HBV-integrated sites with the methylation levels of the same region of non-cancerous genomes (x-axis). A red cross indicates the position of a region including the integration of HBV. In the background, a white dot shows a genomic region, and a black indicates no data. b Proportion of the HBV-integrated sites in active or inactive chromatin areas. The integrated sites were detected using whole-exome and oncovirome sequencing. Reference genome: the proportion of the base numbers of chromatin states in the normal adult liver defined in ENCODE;7 non-clonal: the proportion of the numbers of integration sites (tag count ≥2, ≤3) in 108 non-cancerous liver samples; clonal: the number of integration sites (tag count ≥5) in 102 tumor samples. The P value was calculated using Fisher’s test. c The methylation levels of all CpG sites in the HBV genome detected by whole-genome bisulfite sequencing of HCC samples
Fig. 5 Integration and methylation of HBV genomes in hepatocellular carcinoma genomes. a Comparison of the methylation levels of the regions of tumor genomes (y-axis) that included the HBV-integrated sites with the methylation levels of the same region of non-cancerous genomes (x-axis). A red cross indicates the position of a region including the integration of HBV. In the background, a white dot shows a genomic region, and a black indicates no data. b Proportion of the HBV-integrated sites in active or inactive chromatin areas. The integrated sites were detected using whole-exome and oncovirome sequencing. Reference genome: the proportion of the base numbers of chromatin states in the normal adult liver defined in ENCODE;7 non-clonal: the proportion of the numbers of integration sites (tag count ≥2, ≤3) in 108 non-cancerous liver samples; clonal: the number of integration sites (tag count ≥5) in 102 tumor samples. The P value was calculated using Fisher’s test. c The methylation levels of all CpG sites in the HBV genome detected by whole-genome bisulfite sequencing of HCC samplesCC BY · PubMed Central
Fig. 6 Somatic structural alterations of the cancer and integrated virus genomes. a The density of somatic rearrangements in five tumor samples. The color indicates the number of rearrangements per 10 million bases calculated for each fraction of the images in Supplementary Fig. 5a, which were divided into 25 × 25 areas. The x-axis indicates the size of the region and the y-axis indicates the methylation level of the region. All rearrangements in these samples are shown in Supplementary Data 1. b Accumulation of rearrangements according to different methylation levels of tumor (y-axis) and non-cancerous (x-axis) genomes. Red indicates the number of rearrangements per 10 million bases calculated for each fraction of the images in the upper left in Fig. 1a. c Comparison of the accumulation of rearrangements between active and inactive chromatin areas. d The proportion of somatic rearrangements in active and inactive chromatin areas analyzed using whole-genome sequencing (WGS) of 21 HCCs. In the active areas, deletions, translocations, and inversions were significantly enriched compared with those in the inactive areas. *P < 0.05, **P < 0.005, ***P < 0.0005 using the Χ2-test. e Structural rearrangements of the HBV and human genomes in five samples. Red line: HBV internal rearrangement; black: HBV and human genome breakpoint; blue: human genome rearrangement. f Six long reads from PacBio WGS of the HX25 tumor, including the complex rearrangement of viral and human genome sequences. The integrated or rearranged site was validated by at least two short reads obtained by the Illumina platform
Fig. 6 Somatic structural alterations of the cancer and integrated virus genomes. a The density of somatic rearrangements in five tumor samples. The color indicates the number of rearrangements per 10 million bases calculated for each fraction of the images in Supplementary Fig. 5a, which were divided into 25 × 25 areas. The x-axis indicates the size of the region and the y-axis indicates the methylation level of the region. All rearrangements in these samples are shown in Supplementary Data 1. b Accumulation of rearrangements according to different methylation levels of tumor (y-axis) and non-cancerous (x-axis) genomes. Red indicates the number of rearrangements per 10 million bases calculated for each fraction of the images in the upper left in Fig. 1a. c Comparison of the accumulation of rearrangements between active and inactive chromatin areas. d The proportion of somatic rearrangements in active and inactive chromatin areas analyzed using whole-genome sequencing (WGS) of 21 HCCs. In the active areas, deletions, translocations, and inversions were significantly enriched compared with those in the inactive areas. *P < 0.05, **P < 0.005, ***P < 0.0005 using the Χ2-test. e Structural rearrangements of the HBV and human genomes in five samples. Red line: HBV internal rearrangement; black: HBV and human genome breakpoint; blue: human genome rearrangement. f Six long reads from PacBio WGS of the HX25 tumor, including the complex rearrangement of viral and human genome sequences. The integrated or rearranged site was validated by at least two short reads obtained by the Illumina platformCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 60

Metadata

Authors
Hama, N., Totoki, Y., Miura, F., Tatsuno, K., Saito-Adachi, M., Nakamura, H., Arai, Y., Hosoda, F., Urushidate, T., Ohashi, S., Mukai, W., Hiraoka, N., Aburatani, H., Ito, T., & Shibata, T.
Affiliations
  • National Cancer Center Research Institute (JP)
  • Kyushu University (JP)
  • Research Center for Advanced Science and Technology, The University of Tokyo (JP)
  • Institute of Medical Science, The University of Tokyo (JP)
  • National Cancer Center Hospital (JP)
  • National Cancer Centre Japan (JP)
Corresponding author
Shibata, Tatsuhiro
Venue
Nature Communications
Published
2018-04-24
Volume
9
Issue
1
Pages
1643-1643
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2801984350
Cited by
60
References
42
Citations by year
2026: 4 · 2025: 4 · 2024: 9 · 2023: 7 · 2022: 8 · 2021: 12 · 2020: 5 · 2019: 7 · 2018: 3
FWCI
2.40
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Japan Agency for Medical Research and Development (CREST)
  • University of Tokyo
  • Japan Society for the Promotion of Science (18K07956, 17K07195)
  • Japan Science and Technology Agency (CREST)
  • Core Research for Evolutional Science and Technology
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords
liver cancer, epigenetic modifications, DNA methylation, chromatin state, somatic mutations, structural rearrangement, viral integration, mutational signatures, inactive chromatin, carcinogenesis
MeSH terms
Adult, Aged, Chromatin, Female, Hepatitis B virus, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Mutation, Genome, Human, Virus Integration, Genome, Viral, DNA Methylation, Epigenomics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Epigenetic landscape influences the liver cancer genome architecture. https://app.cochat.ai/papers/10.1038/s41467-018-03999-y
The paper
Hama, N., Totoki, Y., Miura, F., Tatsuno, K., Saito-Adachi, M., Nakamura, H., Arai, Y., Hosoda, F., Urushidate, T., Ohashi, S., Mukai, W., Hiraoka, N., Aburatani, H., Ito, T., & Shibata, T. (2018). Epigenetic landscape influences the liver cancer genome architecture. Nature Communications. https://doi.org/10.1038/s41467-018-03999-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.